Radiosintesi e preliminare valutazione biologica del [18F]VC701, antagonista del recettore PBR, potenzialmente applicabile allo studio di patologie neurodegenerative e strategie di marcatura di nanoparticelle polimeriche con preliminare valutazione del loro targeting in vivo

The evaluation of N-benzyl-3-fluoromethyl-N-[11C]methyl-4-phenyl-2-quinolincarboxamide, a promising radioligand for in vivo TSPO imaging with Positron Emission Tomography (PET), led to the labelling of its chloromethyl precursor with the longer living positron emitter radioisotope Fluorine-18 (t1/2= 109.8 min) to perform long-time kinetic studies. N-benzyl-3-[18F]fluoromethyl-N-methyl-4-phenyl-2-quinolincarboxamide was obtained with a good chemical and radiochemical purity and a good specific activity. Initial pre-clinical data demonstrated that it is a promising tracer, showing a good signal-noise ratio in target organs of healthy rats. These results encourage further evaluation of this radioligand also in lesioned areas of CNS, characteristic of some important neuropathologies.